Researchers in the United States have evaluated the association between deprescribing acetylcholinesterase inhibitors (AChEIs) and all-cause negative events such as hospitalisation, emergency department visits and mortality, as well as serious falls or fractures, in nursing home (NH) residents with severe dementia. This study arises from the risk of medication-induced adverse events and the unclear effectiveness of continued AChEI use in this population. 37,106 NH residents with severe dementia aged ≥ 65 years were enrolled in the study. It was reported that deprescribing AChEIs was not significantly associated with incidence of all-cause negative events, but it was associated with a decreased risk of hospitalisation due to falls or fractures (odds ratio 0.59; 95% CI 0.52‐0.66; P < 0.001). These findings are key to understanding the tolerability and safety of AChEI deprescribing in NH residents with severe dementia, suggesting that discontinuation is a practical approach to reducing the risk of serious falls or fractures without increasing the likelihood of negative events. The original research can be viewed here.